Skip to content

Shendi Granules on PBMC apoptosis and MCP-1, TGF- beta 1 in chronic glomerulonephritis patients with spleen and kidney deficiency syndrome

Shendi Granules on PBMC apoptosis and MCP-1, TGF- beta 1 in chronic glomerulonephritis patients with spleen and kidney deficiency syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17011060
Enrollment
Unknown
Registered
2017-04-05
Start date
2017-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic glomerulonephritis

Interventions

treatment group:conventional therapy+Shendi Granules
control group:conventional therapy+Valsartan

Sponsors

the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. To meet the diagnostic criteria of CGN and spleen and kidney deficiency syndrome differentiation standard; 2. Chronic kidney disease I, II (glomerular filtration rate >60ml / min); 3. 24h urinary protein <3g;4.Age from 18 to 70 years old.

Exclusion criteria

Exclusion criteria: 1. Who are already taking corticosteroids or cytotoxic drugs; 2. Women who are pregnant or nursing women with severe primary diseases such as heart, brain, liver and blood system; 3. Can not according to the prescribed medication,impact of the judgement; 4. Those whose data are incomplete and can not determine the efficacy.

Design outcomes

Primary

MeasureTime frame
24 hour urine protein quantitation;serum creatinine;Urea nitrogen;

Secondary

MeasureTime frame
TCM Syndrome;

Countries

China

Contacts

Public ContactYiping Wang

the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

wypwyp54@aliyun.com+86 13075580986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026